71 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up http://www.zacks.com/stock/news/357477/endo-endp-q4-earnings-revenues-beat-estimates-shares-up?cid=CS-ZC-FT-357477 Mar 01, 2019 - Endo's (ENDP) earnings and revenues top expectations in the fourth quarter.
Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC http://www.zacks.com/stock/news/358374/roches-rhhby-tecentriq-gets-ec-nod-for-first-line-nsclc?cid=CS-ZC-FT-358374 Mar 08, 2019 - Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $15. ... http://www.gurufocus.com/news/835656/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-158-million-of-shares Mar 20, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $15.8 million of Shares, Stocks: MRK, release date:Mar 20, 2019
Glaxo Presents Encouraging Data on Endometrial Cancer Drug http://www.zacks.com/stock/news/362265/glaxo-presents-encouraging-data-on-endometrial-cancer-drug?cid=CS-ZC-FT-362265 Mar 20, 2019 - Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition http://www.zacks.com/stock/news/362782/bristol-myers-celgene-buyout-still-uncertain-amid-opposition?cid=CS-ZC-FT-362782 Mar 21, 2019 - The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.
Seattle Genetics, Astellas Report Positive Cancer Study Data http://www.zacks.com/stock/news/367467/seattle-genetics-astellas-report-positive-cancer-study-data?cid=CS-ZC-FT-367467 Mar 29, 2019 - Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.
3 Big Pharma Stocks to Add to Your Portfolio This April http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-ZC-FT-368171 Apr 01, 2019 - The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval http://www.zacks.com/stock/news/371316/dow-30-stock-roundup-wba-q2-earnings-disappoint-pfe-lung-cancer-drug-gets-eu-approval?cid=CS-ZC-FT-371316 Apr 05, 2019 - The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU http://www.zacks.com/stock/news/371503/pharma-stock-roundup-nvs-inks-immunology-deal-pfe-teva-get-drug-approvals-in-eu?cid=CS-ZC-FT-371503 Apr 05, 2019 - Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

Pages: 12345678

<<<Page 5>